- Home
- MRVL vs NVO Comparison
MRVL vs NVO Comparison
Compare MRVL & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVL | NVO |
|---|---|---|
| Founded | 1995 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.9B | 197.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRVL | NVO |
|---|---|---|
| Price | $316.42 | $43.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 32 | 11 |
| Target Price | ★ $120.28 | $51.00 |
| AVG Volume (30 Days) | ★ 49.1M | 10.9M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | 0.15% | ★ 3.19% |
| EPS Growth | ★ 400.98 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $8,194,600,000.00 | N/A |
| Revenue This Year | $35.14 | N/A |
| Revenue Next Year | N/A | $3.70 |
| P/E Ratio | $7,307.50 | ★ $13.60 |
| Revenue Growth | ★ 42.09 | N/A |
| 52 Week Low | $61.44 | $35.12 |
| 52 Week High | $324.20 | $71.80 |
Technical Indicators
Market Signals| Indicator | MRVL | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 66.11 | 47.58 |
| Support Level | $76.86 | $41.05 |
| Resistance Level | $324.20 | $50.30 |
| Average True Range (ATR) | 30.72 | 1.34 |
| MACD | 1.13 | -0.09 |
| Stochastic Oscillator | 94.51 | 45.47 |
Price Performance
Historical ComparisonAbout MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.